Literature DB >> 22343486

c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.

Xinqi Wu1, Jun Zhou, Andrew M Rogers, Pasi A Jänne, Elisa Benedettini, Massimo Loda, F Stephen Hodi.   

Abstract

Uveal melanoma (UM) has a high propensity to develop hepatic metastases. We sought to define the mechanisms required for preferential liver homing and to understand further the biologic behavior of this disease. The Met tyrosine kinase receptor and its ligand hepatocyte growth factor are expressed in hepatocytes. We therefore considered Met/hepatocyte growth factor signaling as a candidate migration/growth factor for UM cells. We further explored the relationship between c-Met and other growth factor receptors prevalent in the liver and their roles in UM metastatic potential. UM cell lines were evaluated for c-Met, epidermal growth factor receptor (EGFR), and insulin-like growth factor-1R (IGF-1R) expression by immunoblotting, and gene amplification by comparative genomic hybridization and fluorescence in-situ hybridization. High c-Met, phosphorylated c-Met, and EGFR expression were noted in two of nine cell lines, independent of IGF-1R levels. Knockdown of c-Met decreased proliferation of high c-Met-expressing UM cells but did not induce apoptosis. Selective inhibitors of EGFR and IGF-1R decreased proliferation and induced apoptosis in UM cells regardless of the expression levels of c-Met, EGFR, and IGF-1R. Although c-Met, EGFR, and IGF-1R play proliferative roles, EGFR and IGF-1R are also critical for UM cell survival. High c-Met/EGFR-expressing cell lines possessed the greatest migration potential. c-Met knockdown and selective inhibitors of c-Met, EGFR, and IGF-1R revealed independent contribution of these receptors to migration. UM can be categorized by levels of c-Met and EGFR expression which are associated with migratory/invasiveness responses to soluble factors present at high levels in the liver. This provides biologic relevance for UM clinical behavior with potential therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343486     DOI: 10.1097/CMR.0b013e3283507ffd

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  21 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

3.  Characterization of extracellular vesicles isolated from different liquid biopsies of uveal melanoma patients.

Authors:  Carmen Luz Pessuti; Deise Fialho Costa; Kleber S Ribeiro; Mohamed Abdouh; Thupten Tsering; Heloisa Nascimento; Alessandra G Commodaro; Allexya Affonso Antunes Marcos; Ana Claudia Torrecilhas; Rubens N Belfort; Rubens Belfort; Julia Valdemarin Burnier
Journal:  J Circ Biomark       Date:  2022-06-27

Review 4.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

5.  EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Swapna Asuthkar; Bharathi Gorantla; Andrew J Tsung
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

6.  Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Authors:  Andreas Varkaris; Sanchaika Gaur; Nila U Parikh; Jian H Song; Farshid Dayyani; Jung-Kang Jin; Christopher J Logothetis; Gary E Gallick
Journal:  Int J Cancer       Date:  2013-04-17       Impact factor: 7.396

7.  First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

Authors:  Aiwu Ruth He; Roger B Cohen; Crystal S Denlinger; Ashwin Sama; Ariel Birnbaum; Jimmy Hwang; Takami Sato; Nancy Lewis; Michelle Mynderse; Michele Niland; Jennifer Giles; Johan Wallin; Brian Moser; Wei Zhang; Richard Walgren; Elizabeth R Plimack
Journal:  Oncologist       Date:  2019-03-04

Review 8.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

9.  Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells.

Authors:  Song-Tao Xu; Xiang Ding; Qing-Feng Ni; Shao-Ju Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.

Authors:  Xinqi Wu; Melina E Marmarelis; F Stephen Hodi
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.